What kind of medicine is Bituvi/Bikonprenol Tablets? Comprehensive analysis of efficacy and mechanism of action

Biktarvy is a compound drug used to treat HIV-1 (human immunodeficiency virus type 1) infection. It consists of three ingredients: Bictegravir (BIC), Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF). Bituvir is an oral treatment regimen typically used in treatment-naïve patients or those who have achieved virologic suppression and who have not developed resistance mutations during treatment. As a three-in-one drug, Bituvi works synergistically to prevent HIV virus replication, thereby helping patients maintain a lower viral load and delay immune system damage.

Bictegravir sodium is a type of Integrase inhibitor in BituvitIntegrase inhibitor, which inhibits the replication of the virus by blocking the integration of HIV virus into the DNA of host cells. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors, which further reduce viral replication by inhibiting the reverse transcription process of the HIV virus. Through these mechanisms, Bituvi can effectively reduce the viral load of HIV, help infected people maintain long-term immune function, and prevent the occurrence of AIDS.

Bitavi is indicated for use in adult patients who are antiretroviral-naïve and who have achieved virologic suppression on existing antiretroviral therapy and who do not have drug-resistant mutations. The advantage of Bituvit is that it is an oral compound drug that only needs to be taken once a day, simplifying the treatment plan and enhancing patient compliance. For those HIV patients who are receiving long-term treatment, Bituvi is also an ideal alternative drug, which can effectively prevent the rebound of the virus.

Reference materials:https://www.biktarvy.com/